This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

The goal of this activity is to increase clinicians' understanding of the immune system and avenues of immune modulation beyond the currently available checkpoint inhibitors.

Learning Objectives:

• Have increased knowledge regarding the unmet medical need in patients with cancer whose disease does not respond to or becomes resistant to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and/or cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition

• Have increased knowledge regarding the avenues of immune modulation beyond PD-1/PD-L1 and CTLA-4 inhibition to improve immune recognition of cancer cells and tumors

• Have increased knowledge regarding the mid-to-late stage clinical trial data on the use of novel strategies to modulate the immune system to treat patients with cancer

Approximate Time to Complete: 30 minutes

Credit Available: December 23rd, 2020 - December 23rd, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Certificate in Cancer Immunotherapy